drugset / Trial / NCT02890966

Multiple Dose Study of SHR4640 in Healthy Subjects

NCT02890966

Phase 1 Completed 48 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study is to assess the tolerance, pharmacokinetic and pharmacodynamic properties of multiple dose adminstration of SHR4640 in healthy volunteers.

Timeline

Start
2016-07
Primary completion
2017-02
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR4640 Small molecule 1 mg Oral
Subject SHR4640 Small molecule 2.5 mg Oral
Subject SHR4640 Small molecule 5 mg Oral
Subject SHR4640 Small molecule 10 mg Oral

Indications